Supplemental Financial Information - Schedule of Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands		6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022
ROU assets obtained in exchange for new operating lease liabilities upon adoption of ASC 842		$ 0
ROU assets obtained in exchange for new finance lease liabilities upon adoption of ASC 842		0
ROU asset obtained in exchange for new operating lease liabilities		13,649
ROU Asset obtained in exchange for new finance lease liabilities		0
Purchases of property and equipment included in accounts payable and accrued expenses		2,324
Equity received in related parties		0
Convertible financial instruments received for Cell Engineering services		5,595
Equity securities and warrants received for Cell Engineering services		12,493
Settlement of contingent consideration - restricted stock		2,262
Common stock issued for business and asset acquisitions		3,581
Contingent consideration for business acquisition		$ 0
As Adjusted [Member]
ROU assets obtained in exchange for new operating lease liabilities upon adoption of ASC 842	[1]		$ 147,744
ROU assets obtained in exchange for new finance lease liabilities upon adoption of ASC 842	[1]		3,397
ROU asset obtained in exchange for new operating lease liabilities	[1]		28,000
ROU Asset obtained in exchange for new finance lease liabilities	[1]		1,096
Purchases of property and equipment included in accounts payable and accrued expenses	[1]		6,741
Equity received in related parties	[1]		8,873
Convertible financial instruments received for Cell Engineering services	[1]		11,939
Equity securities and warrants received for Cell Engineering services	[1]		3,423
Settlement of contingent consideration - restricted stock	[1]		0
Common stock issued for business and asset acquisitions	[1]		17,015
Contingent consideration for business acquisition	[1]		$ 12,306

[1] * As adjusted to reflect the impact of the adoption of ASC 842 as of January 1, 2022. See Note 1 for a summary of the adjustments.